Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

symptoms in adults and children aged 12 years and older.

ARCALYST is in a Phase 3 clinical development program for the treatment of gout. The program includes four clinical trials, all of which are currently enrolling patients. Two Phase 3 clinical trials (called PRE-SURGE 1 and PRE-SURGE 2) are evaluating ARCALYST versus placebo for the prevention of gout flares in patients initiating urate-lowering drug therapy. A third Phase 3 trial in acute gout (SURGE) is evaluating treatment with ARCALYST alone versus ARCALYST in combination with a non-steroidal anti-inflammatory drug (NSAID) versus an NSAID alone. The fourth Phase 3 trial is a placebo-controlled safety study (RE-SURGE). The Company expects to report initial data from the Phase 3 program in the first half of 2010. Regeneron owns worldwide rights to ARCALYST (rilonacept).

Aflibercept (VEGF Trap) - Oncology

Aflibercept, an anti-angiogenic protein product candidate designed to bind all forms of vascular endothelial growth factor A (VEGF-A), is being developed worldwide by Regeneron and its collaborator, sanofi-aventis. At the end of the third quarter of 2009, more than 80 percent of the planned number of patients were enrolled in each of three Phase 3 trials that are evaluating combinations of aflibercept with standard chemotherapy regimens for the treatment of cancer. One trial (called VELOUR) is evaluating aflibercept as a 2nd line treatment for metastatic colorectal cancer in combination with FOLFIRI (folinic acid (leucovorin), 5-fluorouracil, and irinotecan). A second trial (VITAL) is evaluating aflibercept as a 2nd line treatment for metastatic non-small cell lung cancer in combination with docetaxel. The third trial (VENICE) is evaluating aflibercept as a 1st line treatment for metastatic androgen-independent prostate cancer in combination with docetaxel/prednisone. All three trials are studying the current standard of chemotherapy care for the cancer bei
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... -- - CPhI and P-MEC China 2015 ... Shanghai, China - The 15th ... held at Shanghai New International Expo Center, on 24th June, ... Worldwide and was introduced to China in 2001. It has ... companies and global pharmaceutical industry over the past 15 years. ...
(Date:3/3/2015)... , Mar. 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cardiovascular Drug Delivery - ... , Drug delivery to the cardiovascular system ... the anatomy and physiology of the vascular system; it ... body. Drugs can be introduced into the vascular system ...
(Date:3/3/2015)... , March 3, 2015  HeartIT is pleased ... first Cardiac Magnetic Resonance Solution in the market ... a standard web browser. Precession™ combines zero footprint ... unmatched in the industry. This provides CMR professionals ... the critical functions of a successful CMR program. ...
Breaking Medicine Technology:15th Anniversary, Be Part of Chinese Pharma Dream 215th Anniversary, Be Part of Chinese Pharma Dream 3Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 2Global Cardiovascular Drug Delivery Technologies, Markets and Companies 2014-2024 3Precession Advances Medical Imaging by Delivering a Complete Cardiac Magnetic Resonance Platform in a Web Browser 2
(Date:3/3/2015)... Introducing 3D Digital Technologies to ... recognized leader in Digital Dentistry. Acute precision in ... dental replicas, leaving no room for error during ... professionals are able to significantly reduce “chair time” ... remarkable quality while reducing labor and material costs ...
(Date:3/3/2015)... March 03, 2015 Birth Boot ... today they now have over 130 certified instructors in ... in Germany. In addition, the company recently launched a ... childbirth educator certification program . Birth Boot Camp ... her birth partner. The practical information can be used ...
(Date:3/3/2015)... March 03, 2015 The FSH ... science of the little-known and incurable disease, facioscapulohumeral muscular ... #CureFSHD campaign . The purpose of the campaign is ... of the most common forms of muscular dystrophies. ... campaign, today the FSH Society will begin sharing impactful ...
(Date:3/3/2015)... Jack Coats, Chief Executive Officer of ... Breukelman has been named to the company’s Board of ... first fully integrated version of its Multiparametric Strain Analysis ... three-dimensional motion of the heart that is acquired from ... 15,300 points to the motion of a normal heart ...
(Date:3/3/2015)... March 03, 2015 Raritan Bay Medical ... of Health,” an interactive photo contest held at the ... 8, 2015. To raise awareness for health and wellness ... to share their best health and wellness tips. , ... Bay Medical Center’s website and Facebook page where Facebook ...
Breaking Medicine News(10 mins):Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 2Health News:Iverson Dental Labs Introduces 3D Digital Dental Technology for Superior Products 3Health News:Expectant Couples Worldwide Can Now Receive Training and Education in Natural Childbirth and Breastfeeding from Birth Boot Camp 2Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 2Health News:Share to be Aware: FSH Society Launches #CureFSHD Campaign 3Health News:William A. (Bill) Breukelman Named to CardioWise, Inc. Board of Directors 2Health News:William A. (Bill) Breukelman Named to CardioWise, Inc. Board of Directors 3Health News:Raritan Bay Medical Center Announces Winners of “Picture of Health” Photo Contest 2
... Hodgkins Lymphoma should be especially vigilant about cancer ... Forest University Baptist Medical Center and colleagues. , ... Society of Clinical Oncology in Chicago today, Sharon ... study of 1,927 Hodgkins survivors found that treatments ...
... prolonged progression-free survival, study finds , , SATURDAY, May ... to chemotherapy lengthened progression-free survival in women with ... studies have found that adding Avastin (bevacizumab) to ... advanced breast cancer actually doubled progression-free survival. , ...
... 2008) -- Leading oncologists and cancer researchers at ... basic and clinical research findings at the 44th ... in Chicago, May 30 to June 3. , ... be made by NewYork-Presbyterian/Weill Cornell physician-scientists include the ...
... May 30 Hero Nutritionals,introduced Slice of Life, a ... Products Expo West in March 2008. Included in the ... CoQ10 is found in every cell in,the body, its ... for ,found everywhere, low levels of the vital nutrient ...
... of Asthmatics Applauds FDA Public Health ... Patients Need to Know, FAIRFAX, Va., May 30 ... not know that at the end of this,year, their ... using chlorofluorocarbon (CFC) albuterol metered-dose inhalers (MDIs),to switch to ...
... ... year-over-year to $87.5 ... beds served increased 8.5% year-over-year to 65,700 at March 31, 2008 - First quarter ... - Stock symbol changed to CHRX from PMQC, LONG BEACH, N.Y., May ...
Cached Medicine News:Health News:Survivors of childhood Hodgkin's lymphoma at higher risk of future health problems 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 2Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 3Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 4Health News:Get the Facts on the Albuterol Inhaler Transition 2Health News:Get the Facts on the Albuterol Inhaler Transition 3Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 2Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 3Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 4Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 5Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 6Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 7Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 8Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 9
... (1.5x) Gonio lens will enable visualization of ... mirror lens is the industry preferred standard ... features : , Crispest, clearest imaging ... unattainable with Gonio lenses., 4 equally angled ...
... alternative to bulky biometry devices that have ... AP2000 is the world's only battery-operated, fully ... the market today. Each unit weighs a ... perform multiple functions, namely: auto data capture, ...
... The PiGalileo™ ... System from PLUS ... Surgery technology and ... technologies to assist ...
... a low TLR (<1%) and stroke rate ... and long-term durability., , , High Radial ... carotid artery, increasing lumen diameter with chronic ... Minimal stent shortening, low profile design, Cordis ...
Medicine Products: